163 related articles for article (PubMed ID: 37758909)
1. N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.
Liang Y; Yin W; Cai Z; Luo H; Liu Q; Zhong C; Chen J; Lin Z; Huang Y; Liang Z; Deng J; Zhong W; Cai C; Lu J
Hum Genet; 2023 Sep; ():. PubMed ID: 37758909
[TBL] [Abstract][Full Text] [Related]
2. A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.
Lu J; Chen J; Lin Z; Liu Q; Zhong C; Cai Z; Jia Z; Zhong W; Liang Y; Cai C
Transl Oncol; 2023 Jul; 33():101670. PubMed ID: 37060728
[TBL] [Abstract][Full Text] [Related]
3. Identification and comparison of m6A modifications in glioblastoma non-coding RNAs with MeRIP-seq and Nanopore dRNA-seq.
Krusnauskas R; Stakaitis R; Steponaitis G; Almstrup K; Vaitkiene P
Epigenetics; 2023 Dec; 18(1):2163365. PubMed ID: 36597408
[TBL] [Abstract][Full Text] [Related]
4. Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.
Liu J; Zhang W; Wang J; Lv Z; Xia H; Zhang Z; Zhang Y; Wang J
J Cancer Res Clin Oncol; 2023 May; 149(5):1969-1983. PubMed ID: 35731271
[TBL] [Abstract][Full Text] [Related]
5. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
6. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
7. The potential role of N6-methyladenosine modification of LncRNAs in contributing to the pathogenesis of chronic glomerulonephritis.
Liu T; Zhuang XX; Qin XJ; Wei LB; Gao JR
Inflamm Res; 2023 Mar; 72(3):623-638. PubMed ID: 36700958
[TBL] [Abstract][Full Text] [Related]
8. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.
Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X
Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983
[TBL] [Abstract][Full Text] [Related]
10. Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma.
Lin G; Wang H; Wu Y; Wang K; Li G
Front Mol Biosci; 2021; 8():682471. PubMed ID: 34295922
[No Abstract] [Full Text] [Related]
11. Mutator-Derived lncRNA Landscape: A Novel Insight Into the Genomic Instability of Prostate Cancer.
Tang L; Li W; Xu H; Zheng X; Qiu S; He W; Wei Q; Ai J; Yang L; Liu J
Front Oncol; 2022; 12():876531. PubMed ID: 35860569
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
[No Abstract] [Full Text] [Related]
13. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
14. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H
BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043
[TBL] [Abstract][Full Text] [Related]
16. N6-methyladenosine methylation mediates non-coding RNAs modification in microplastic-induced cardiac injury.
Zhang M; Shi J; Zhou J; Song L; Ding J; Deng HP; Weng L; Zhu Y; Xu Z
Ecotoxicol Environ Saf; 2023 Jun; 262():115174. PubMed ID: 37354568
[TBL] [Abstract][Full Text] [Related]
17. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma.
Ma T; Wang X; Wang J; Liu X; Lai S; Zhang W; Meng L; Tian Z; Zhang Y
Front Genet; 2021; 12():726369. PubMed ID: 34721523
[TBL] [Abstract][Full Text] [Related]
18. Identification of m6A-related lncRNAs for thyroid cancer recurrence.
Wang X; Su D; Wei Y; Liu S; Gao S; Tian H; Wei W
Gland Surg; 2023 Jan; 12(1):39-53. PubMed ID: 36761480
[TBL] [Abstract][Full Text] [Related]
19. Validated Impacts of N6-Methyladenosine Methylated mRNAs on Apoptosis and Angiogenesis in Myocardial Infarction Based on MeRIP-Seq Analysis.
Zhang Y; Hua W; Dang Y; Cheng Y; Wang J; Zhang X; Teng M; Wang S; Zhang M; Kong Z; Lu X; Zheng Y
Front Mol Biosci; 2021; 8():789923. PubMed ID: 35155564
[No Abstract] [Full Text] [Related]
20. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
